ACM
VKTX icon

ACT Capital Management’s Viking Therapeutics VKTX Stock Holding History

ACT Capital Management’s Portfolio VKTX Stock Details VKTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$6.81M Buy
209,300
+3,200
+2% +$103K 5.35% 8
2025
Q4 		$7.25M Buy
+206,100
New +$7.3M 5.86% 6
2021
Q3 		– Sell
-128,500
Closed -$770K – 134
2021
Q2 		$770K Buy
+128,500
New +$763K 0.4% 49

Other funds holding VKTX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Raymond James Financial
Raymond James Financial St Petersburg, Florida $324B AUM 22.36% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
American Century Companies
American Century Companies Kansas City, Missouri $194B AUM 35% 1-Year Est. Return

ACT Capital Management's VKTX Position: Q1 2026 in Review

ACT Capital Management increased its Viking Therapeutics (VKTX) stake by 1.6% in Q1 2026, buying an estimated $103K and bringing the position to 209,300 shares worth $6.81M. The position accounts for 5.35% of the portfolio, ranked #8.

ACT Capital Management first reported a position in VKTX in Q2 2021 and has held it in 3 quarters since. The position peaked at $7.25M in Q4 2025. 410 funds tracked by Wall St. Rank hold VKTX as of Q1 2026.

  • ACT Capital Management held 209,300 shares of Viking Therapeutics worth $6.81M as of Q1 2026.
  • ACT Capital Management bought 3,200 Viking Therapeutics shares in Q1 2026, an estimated $103K.
  • Viking Therapeutics made up 5.35% of ACT Capital Management's portfolio in Q1 2026, its #8 holding.
  • ACT Capital Management first reported a position in Viking Therapeutics in Q2 2021 and has held it in 3 quarters since.
  • ACT Capital Management's Viking Therapeutics position peaked at $7.25M in Q4 2025.
  • 410 funds tracked by Wall St. Rank held Viking Therapeutics as of Q1 2026.

Based on ACT Capital Management's 13F filing for Q1 2026, filed 8 May 2026.